Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,111 Related to Vascepa(R) and Planned ANCHOR

Amarin Announces Notification of Patent Allowance for U.S. Application
13/614,111 Related to Vascepa(R) and Planned ANCHOR Indication

Broadens ANCHOR Vascepa Claims With a Wider Range of EPA Concentrations

BEDMINSTER, N.J., and DUBLIN, Ireland, March 7, 2013 (GLOBE NEWSWIRE) --
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health, announced today that the United States Patent and
Trademark Office (USPTO) has published notification of a Notice of Allowance
for Amarin's U.S. Patent Application Serial Number 13/614,111titled "Stable
Pharmaceutical Compositions and Methods of Using the Same." This application
includes claims intended to protect the proposed Vascepa^® (icosapent ethyl)
indication based on Amarin'sPhase 3 ANCHOR clinical trial results. In late
February, Amarin filed a Supplemental New Drug Application for the Vascepa
ANCHOR indication with the U.S. Food and Drug Administration(FDA), and
expects an FDA action date on the application before the end of 2013.

A Notice of Allowance is issued after the USPTO makes a determination that a
patent can be granted from an application. The issued patent would have a term
that expires no earlier than in 2030. Amarin plans to list this patent in the
FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or
Orange Book, after issuance of the patent and the anticipated approval of
Vascepa in the ANCHOR indication.

The claims in this allowed application relate to the planned Vascepa ANCHOR
indication and cover methods of treating mixed dyslipidemia through the daily
administration of 2500 mg to 5000 mg of highly pure EPA to a subject on any
statin therapy. 

"The claims in this allowed application cover the described method of
administration of a pharmaceutical composition comprising EPA over a broader
range of daily EPA doses and amounts of EPA per capsule including, for
example, a daily dosing regimen of four capsules, each containing
approximately 62.5% EPA and 37.5% of one or more other components," stated
Joseph Zakrzewski, Chairman and Chief Executive Officer of Amarin. "The
issuance of this Notice of Allowance represents the broadest ANCHOR patent to

This application is part of an expanding patent portfolio for Amarin with 19
patent applications now either issued or allowed with the USPTO and over 30
additional applications pending in the United States. Amarin is also pursuing
patent applications related to Vascepa in multiple jurisdictions outside the
United States, including the application for Amarin's MARINE method of use
patent in Europe for which Amarin has announced receipt of an Intention to
Grant letter.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA and available by prescription. For more
information about Vascepa visit For more information about
Amarin visit

The Amarin Corporation plc logo is available at

Forward-looking statements

This press release contains forward-looking statements, including statements
about whether the subject patent would be issued and adequately protect
Vascepa against competition, the expiration date of the pending patent,
Amarin's plan to list the patent, when issued, in FDA's Orange Book assuming
FDA approval of the ANCHOR indication, the anticipated approval of Vascepa in
the ANCHOR indication, Amarin's plan to protect the commercial potential of
Vascepa, the future status of pending patent applications, planned regulatory
submissions and expected action dates. These forward-looking statements are
not promises or guarantees and involve substantial risks and uncertainties.
Among the factors that could cause actual results to differ materially from
those described or projected herein include the following: events that could
interfere with the issuance of a patent, or once issued, the continued
validity or enforceability of a patent; Amarin's ability generally to maintain
adequate patent protection and successfully enforce patent claims against
third parties; commercializing Vascepa without violating the intellectual
property rights of others; and uncertainties associated generally with
research and development, clinical trial enrollment in Amarin's REDUCE-IT
trial and related regulatory submissions, action dates and approvals. A
further list and description of these risks, uncertainties and other risks
associated with an investment in Amarin can be found in Amarin's filings with
the U.S. Securities and Exchange Commission, including its most recent Annual
Report on Form 10-K. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which speak only as
of the date hereof. Amarin undertakes no obligation to update or revise the
information contained in this press release, whether as a result of new
information, future events or circumstances or otherwise.

Vascepa has been approved for use by the FDA as an adjunct to diet to lower
triglyceride levels in adult patients with severe (≥500 mg/dL)
hypertriglyceridemia.Vascepa is under various stages of development for
potential use in other indications that have not been approved by the
FDA.Nothing in this press release should be construed as marketing the use of
Vascepa in any indication that has not been approved by the FDA.

         Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315

company logo
Press spacebar to pause and continue. Press esc to stop.